Study of Trametinib and Nab-paclitaxel in Patients With Melanoma
Status:
Withdrawn
Trial end date:
2016-01-20
Target enrollment:
Participant gender:
Summary
This study will investigate the combination of two drugs, trametinib and nab-paclitaxel, in
patients with advanced unresectable or metastatic melanoma. Each drug has shown activity in
trials of patients with melanoma. However, the combination of these two drugs has not been
studied. In this trial the investigators will determine the maximum dose of the drug
combination to be administered to patients with advanced unresectable or metastatic melanoma
and examine the safety profile of the drug combination.